<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029274</url>
  </required_header>
  <id_info>
    <org_study_id>CBAF312X2206</org_study_id>
    <secondary_id>2013-001799-39</secondary_id>
    <nct_id>NCT02029274</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of BAF312 in Dermatomyositis</brief_title>
  <official_title>A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the dose response relationship for the efficacy and safety of BAF312
      compared to placebo in active DM patients over a treatment period of 6+6 months and to
      determine the minimum dose required for a maximal clinical effect. The study is composed of 2
      periods: a double-blind period I with BAF312 administered at different daily doses (0.5, 2,
      10 mg and placebo) and a fixed-dose Period II in which BAF312 will be administered at the
      dose of 2 mg daily .
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Manual Muscle Testing - 24 muscles (MMT-24). Efficacy of BAF312 will be assessed by comparing the improvements with every dose of BAF312 to that of placebo.</measure>
    <time_frame>6 months</time_frame>
    <description>The primary aim of this study is to assess the efficacy of different doses of BAF312 on the MMT-24 after 6 months. The overall efficacy of BAF312 will be assessed by comparing the improvements of MMT-24 with every dose of BAF312 to that of placebo. Then the doseresponse curve of MMT-24 will be estimated with the aim to determine a target dose for the program.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events. All information obtained on adverse events will be displayed by treatment (dose group) and subject.</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary variables include the incidence of adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics. BAF312 plasma concentration data will be listed by treatment (dose group), subject and visit/sampling time point. Descriptive summary statistics will be provided by treatment and visit/sampling time point.</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary variables include plasma BAF312 concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral blood lymphocyte counts. Absolute lymphocyte counts will be plotted against time by dose level.</measure>
    <time_frame>6 months</time_frame>
    <description>Secondary variables include peripheral blood lymphocyte counts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manual Muscle Testing - 24 muscles (MMT-24). Efficacy of BAF312 will be assessed by comparing the improvements with every dose of BAF312 to that of placebo.</measure>
    <time_frame>3 months</time_frame>
    <description>Changes from baseline in MMT-24 at 3 months will also be evaluated. The dose-response will be assessed in the same way as for the 6-month data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 Minutes Walking Distance test. Efficacy of BAF312 will be assessed by comparing the changes in walking distance across all doses of BAF312 to that of placebo</measure>
    <time_frame>6 months</time_frame>
    <description>Changes from baseline in 6 Minute walking distance at 6 months of treatment will be assessed.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Active Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>BAF312 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAF312 0.5 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAF312 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAF312 2 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BAF312 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BAF312 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF312 0.5 mg</intervention_name>
    <description>BAF312 0.5 mg once daily</description>
    <arm_group_label>BAF312 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF312 2 mg</intervention_name>
    <description>BAF312 2 mg once daily</description>
    <arm_group_label>BAF312 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAF312 10 mg</intervention_name>
    <description>BAF312 10 mg once daily</description>
    <arm_group_label>BAF312 10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to BAF312</intervention_name>
    <description>Placebo to BAF312 once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Written informed consent must be obtained before any assessment is performed.

          -  Patients who have been defined as &quot;definite&quot; or &quot;probable&quot; based on the criteria of
             Bohan and Peter (Bohan and Peter 1975) for dermatomyositis at least 3 months before
             screening

          -  Patients must have active disease as defined by muscle weakness

          -  Patients may be on a stable dose of corticosteroid (up/equal to 20 mg once daily
             prednisone equivalent)

          -  Patients currently treated with oral or subcutaneous MTX must have been a stable dose
             of no more/equal to than 25 mg per week

          -  Patients currently treated with Azathioprine must have been a stable maintenance dose
             of no more/equal to 3 mg/kg/day

          -  Negative cancer screening conducted in the 12 months prior to screening visit

        Exclusion Criteria

          -  Dermatomyositis patients having overlap myositis or any other type of myositis
             including paraneoplastic myositis, drug-induced myopathy, necrotizing myositis

          -  Preexisting severe cardiac or pulmonary conditions, malignancy of any organ system or
             significant eye diseases.

          -  Uncontrolled diabetes mellitus or diabetes complicated with organ involvement.

          -  Pregnant or nursing (lactating) women

          -  Other protocol-defined inclusion/exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 2</city>
        <zip>128 50</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba-city</city>
        <state>Chiba</state>
        <zip>260-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai city</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>China</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2013</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <last_update_submitted>September 7, 2016</last_update_submitted>
  <last_update_submitted_qc>September 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dermatomyositis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>November 15, 2016</submitted>
    <returned>January 10, 2017</returned>
    <submitted>February 8, 2017</submitted>
    <returned>March 28, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

